Table 3.
Anti‐Ro60low (n = 25) | Anti‐Ro60high (n = 25) | P‐value | |
---|---|---|---|
Mean follow‐up period (years ± SD) | 2·15 ± 1·20 | 2·68 ± 1·69 | 0·207 |
Additional LIB specificities at baseline (mean ± SD) | 0·64 ± 1·04 | 1·08 ± 1·19 | 0·170 |
Loss/no change/gain of additional LIB specificities by end of follow‐up (n) | 3/21/1 | 4/14/6 | 0·307 |
Additional LIB specificities by end of follow‐up (mean ± SD) | 0·52 ± 0·92* | 1·24 ± 1·01* | 0·011 |
Decreased/same/increased anti‐Ro60 intensity group by end of follow‐up (n) | 4/18/3 | 8/16/1 | 0·294 |
P > 0·05 compared to baseline within the same anti‐Ro60 subset.
Bold value represents significant P < 0·05.
SD = standard deviation; LIB = line immunoblot assay.